Wednesday, October 16, 2013

Post-Doctoral position Epigenetic drug discovery 2014 at GlaxoSmithKline


GlaxoSmithKline is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world. As a company, we also believe in developing talent and people. At GSK, you have the opportunity to make a real contribution in a dynamic and diverse business environment.
Cellzome, a GSK company, based in Heidelberg, applies its world-class proteomics technology to the discovery of safe and effi cacious drugs.
At our site on the EMBL campus in Heidelberg, Germany, we have an opening for a full time
2 years Post-Doctoral position (f/m)
(Start January 1st 2014)
Position:The successful candidate will work on Epigenetic drug discovery. In particular, the focus of the work will be drug target validation and mode of actions of compounds targeting epigenetic factors. She/he will set strategies for studies, implement new methods and combine them with cutting edge chemoproteomic technologies. The position requires work in a multi-disciplinary team and the ability to interact with groups across different lines, GSK sites and academic labs.
Requirements:Recent PhD in biology or biochemistry (0-2 years post-doctoral experience). A background in epigenetic and chromatin biology including familiarity and experience with concepts and broad based epigenetic technologies (i.e. Chip) will be advantageous.

We are looking for a motivated individual with the potential to make a strong impact in novel drug discovery projects in the fi eld of Epigenetics. Flexibility and the ability to work in a team focused on innovative drug discovery are essential. Communication skills and experience in presenting data are important.

Cellzome provides a high quality, international research environment with world-class proteomics capabilities. For a fi rst introduction to Cellzome, please refer to some of recent publications (e.g. Bantscheff, Nat Biotech 2011, Dawson et al., Nature 2011, Bergamini, Nat Chem Biol 2012).
If you want to make a real difference to people’s lives across the globe – and your own career prospects in the process – find out more at www.gsk.com and apply now.
Applicants should send their CV summarizing qualifi cations and experience, including the names and addresses of two referees, no later than 30th November 2013.